Skip to content
ClinCalc Pro
Menu
Potassium-Sparing Diuretic (Epithelial Sodium Channel Blocker) Pregnancy: Not recommended during pregnancy or lactation; potential benefits must be weighed against possible hazards to the foetus.

Amiloride Hydrochloride

Brand names: Midamor

Amiloride is a potassium-sparing diuretic, usually used with a thiazide or loop diuretic to counteract potassium loss and to manage oedema or hypertension.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Initially 10 mg daily or 5 mg twice daily, adjusted according to response
Route: Oral
Frequency: Once or twice daily
Max: 20 mg daily
As adjunct to other diuretics for hypertension and congestive heart failure: initially 5 mg or 10 mg daily. Cirrhosis with ascites: initially 5 mg daily. Elderly: adjust dose according to renal function, blood electrolytes and diuretic response. Not indicated in children under 18 years.

Dose adjustments

Renal

Contraindicated in severe renal impairment; monitor serum electrolytes and blood urea in patients with impaired renal function.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hyperkalaemia
  • Severe renal impairment
  • Prior sensitivity to amiloride
  • Concurrent other potassium-sparing drugs or potassium supplements

Side effects

  • Hyperkalaemia (particularly in elderly, diabetics, renal impairment)
  • Hyponatraemia
  • Nausea, vomiting, constipation or diarrhoea, abdominal pain
  • Postural hypotension, dizziness
  • Rash, pruritus

Interactions

  • ACE inhibitors and angiotensin-II antagonists — enhanced hypotensive effect and increased risk of hyperkalaemia
  • NSAIDs (e.g. indometacin) — increased risk of hyperkalaemia and nephrotoxicity; may antagonise diuretic effect
  • Lithium — reduced renal clearance, high risk of lithium toxicity
  • Other antihypertensives (calcium channel blockers, beta blockers, alpha blockers, hydralazine) — enhanced hypotensive effect
  • Quinidine — antiarrhythmic activity opposed by amiloride

Clinical monograph

How it works

It blocks epithelial sodium channels in the distal nephron, producing a mild natriuresis while reducing potassium and hydrogen ion excretion.

Prescribing in practice

  • Its main hazard is hyperkalaemia, so it should be avoided with other potassium-sparing agents, potassium supplements, and used cautiously with ACE inhibitors, ARBs, or in renal impairment.
  • It is most often prescribed in combination with a potassium-losing diuretic to balance potassium handling.
  • Renal function and potassium must be checked before starting and during treatment, particularly in older or renally impaired patients.

Monitoring

Monitor serum potassium and renal function before and during treatment, especially when combined with other drugs affecting potassium.

Counselling the patient

  • Advise the patient to avoid potassium-containing salt substitutes and over-the-counter potassium supplements unless told otherwise.
  • Explain that blood tests will check kidney function and potassium levels.
  • Suggest taking the dose earlier in the day to limit night-time urination.

Evidence & guidelines

Amiloride is an established potassium-sparing diuretic used to offset diuretic-induced hypokalaemia, with potassium monitoring advised in standard UK prescribing references.

Reference: NICE NG136 (Chronic kidney disease: managing hyperkalaemia, 2020); NICE NG133 (Hypertension in adults, 2019 updated 2023); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.